Identification of new predictive targets with translational potential for canine and human prostatic carcinoma

• Grant number: 22/00593-0
• Support Opportunities: Scholarships in Brazil - Doctorate
• Start date: April 01, 2023
• Status: Discontinued
• Field of knowledge: Biological Sciences - Biology
• Principal Investigator: Carlos Eduardo Fonseca Alves
• Grantee: Alexandre Matheus Baesso Cavalca
• Host Institution: Faculdade de Medicina Veterinária e Zootecnia (FMVZ). Universidade Estadual Paulista (UNESP). Campus de Botucatu. Botucatu , SP, Brazil
• Associated scholarship(s): 24/05997-8 - EVALUATION OF NEW BIOMARKERS AND IDENTIFICATION OF CANCER TARGETED THERAPY FOR CANINE PROSTATIC CARCINOMA, BE.EP.DR

Abstract

The prostate gland is a organ of subjected o aging-related diseases and both benign and malignant prostatic disorders are among the most common diseases affecting men. There are a wide variety of treatment options for the diagnosis of prostate cancer in humans, depending on the risk category the disease falls into. The dog is the only mammal, besides man, that spontaneously develops canine prostatic hyperplasia (PH), prostatic atrophy and prostatic carcinoma (PCa), associated with age, androgenic hormones, in addition to pre-neoplastic lesions, however, in contrast to PCa in humans, PCa in dogs is not androgen dependent, therefore androgen deprivation therapy is not effective, thus developing castration-resistant prostatic carcinoma (CRPC). Many treatment modalities used in usual human PCa cannot be applied in CPRC. And in relation to dogs, unfortunately, there is still no effective therapy for the treatment of these tumors, where the pharmacological treatments available are scarce, based summarily on the prescription of anti-inflammatory drugs, with a low degree of survival. Thus, there is a necessity to carry out new translational studies in human and canine PCa, aiming at the identification of predictive markers and potential common therapeutic targets, elucidating the antitumor effect of existing drugs and aiming at the development of targeted therapies.